{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:50:13Z","timestamp":1789487413356,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"HK inno.N Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-64142-2","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:52:45Z","timestamp":1784908365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of tegoprazan in patients treated with dual antiplatelet therapy after coronary stenting for acute myocardial infarction"],"prefix":"10.1038","volume":"16","author":[{"given":"Oh-Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Jae","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Huan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Woong","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok-Kyu","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongcheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"64142_CR1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine, G. N. et al. ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 68, 1082\u20131115 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"64142_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli, M. et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 39, 213\u2013260 (2018).","journal-title":"Eur. Heart J."},{"key":"64142_CR3","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","volume":"85","author":"SV Rao","year":"2025","unstructured":"Rao, S. V. et al. ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 85, 2135\u20132237 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"64142_CR4","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne, R. A. et al. ESC Guidelines for the management of acute coronary syndromes. Eur. Heart J. 44, 3720\u20133826 (2023).","journal-title":"Eur. Heart J."},{"key":"64142_CR5","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl. J. Med. 361, 1045\u20131057 (2009).","journal-title":"N Engl. J. Med."},{"key":"64142_CR6","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl. J. Med. 357, 2001\u20132015 (2007).","journal-title":"N Engl. J. Med."},{"key":"64142_CR7","doi-asserted-by":"publisher","first-page":"e002053","DOI":"10.1161\/CIRCINTERVENTIONS.114.002053","volume":"8","author":"KC Koskinas","year":"2015","unstructured":"Koskinas, K. C. et al. Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions. Cir. Cardiovasc. Interv. 8, e002053 (2015).","journal-title":"Cir. Cardiovasc. Interv"},{"key":"64142_CR8","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","volume":"363","author":"DL Bhatt","year":"2010","unstructured":"Bhatt, D. L. et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl. J. Med. 363, 1909\u20131917 (2010).","journal-title":"N Engl. J. Med."},{"key":"64142_CR9","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.4244\/EIJ-D-24-00673","volume":"21","author":"D Kang","year":"2025","unstructured":"Kang, D. et al. Effects of proton pump inhibitors on gastrointestinal bleeding and cardiovascular outcomes in myocardial infarction patients treated with DAPT. EuroIntervention 21, e229\u2013e239 (2025).","journal-title":"EuroIntervention"},{"key":"64142_CR10","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1093\/eurheartj\/ehz104","volume":"40","author":"TS Sehested","year":"2019","unstructured":"Sehested, T. S. et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. Eur. Heart J. 40, 1963\u20131970 (2019).","journal-title":"Eur. Heart J."},{"key":"64142_CR11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jacasi.2025.04.010","volume":"5","author":"Y Gong","year":"2025","unstructured":"Gong, Y. et al. Position Statement on Antiplatelet Therapy for East Asians With Coronary Artery Disease: 2025 Update. JACC Asia. 5, 821\u2013846 (2025).","journal-title":"JACC Asia"},{"key":"64142_CR12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.4070\/kcj.2018.0166","volume":"48","author":"J Kang","year":"2018","unstructured":"Kang, J. & Kim, H. S. The evolving concept of dual antiplatelet therapy after percutaneous coronary intervention: focus on unique feature of East Asian and Asian Paradox. Korean Circ. J. 48, 537\u2013551 (2018).","journal-title":"Korean Circ. J."},{"key":"64142_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5009\/gnl230242","volume":"18","author":"BW Kim","year":"2024","unstructured":"Kim, B. W. et al. The effect of tegoprazan on the treatment of endoscopic resection-induced artificial ulcers: a multicenter, randomized, active-controlled study. Gut Liver. 18, 257\u2013264 (2024).","journal-title":"Gut Liver"},{"key":"64142_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/apt.15865","volume":"52","author":"YK Cho","year":"2020","unstructured":"Cho, Y. K. et al. Randomized Clinical Trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment. Pharmacol. Ther. 52, 789\u2013797 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"64142_CR15","doi-asserted-by":"publisher","first-page":"104234","DOI":"10.4253\/wjge.v17.i6.104234","volume":"17","author":"NR Lim","year":"2025","unstructured":"Lim, N. R. & Chung, W. C. Intravenous proton pump inhibitors vs oral potassium competitive acid blockers before endoscopic treatment of bleeding peptic ulcers. World J. Gastrointest. Endosc. 17, 104234 (2025).","journal-title":"World J. Gastrointest. Endosc"},{"key":"64142_CR16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/apt.15438","volume":"50","author":"S Han","year":"2019","unstructured":"Han, S. et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium\u2010competitive acid blocker, in healthy male subjects. Aliment. Pharmacol. Ther. 50, 751\u2013759 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"64142_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/pharmaceutics15010182","volume":"15","author":"LT Ngo","year":"2023","unstructured":"Ngo, L. T., Lee, J., Yun, H. Y. & Chae, J. W. Development of a physiologically based pharmacokinetic model for tegoprazan: application for the prediction of drug\u2013drug interactions with CYP3A4 perpetrators. Pharmaceutics 15, 182 (2023).","journal-title":"Pharmaceutics"},{"key":"64142_CR18","doi-asserted-by":"publisher","first-page":"e2014008","DOI":"10.4178\/epih\/e2014008","volume":"36","author":"L Kim","year":"2014","unstructured":"Kim, L., Kim, J-A. & Kim, S. A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol. Health. 36, e2014008 (2014).","journal-title":"Epidemiol. Health"},{"key":"64142_CR19","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet, J. P. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 42, 1289\u20131367 (2021).","journal-title":"Eur. Heart J."},{"key":"64142_CR20","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.3892\/etm.2016.3693","volume":"12","author":"P Wei","year":"2016","unstructured":"Wei, P. et al. Effects of the short-term application of pantoprazole combined with aspirin and clopidogrel in the treatment of acute STEMI. Exp. Ther. Med. 12, 2861\u20132864 (2016).","journal-title":"Exp. Ther. Med."},{"key":"64142_CR21","doi-asserted-by":"publisher","first-page":"434e1","DOI":"10.1016\/j.jcrc.2010.12.007","volume":"26","author":"H Wu","year":"2011","unstructured":"Wu, H., Jing, Q., Wang, J. & Guo, X. Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes. J. Crit. Care. 26, 434e1\u2013434e6 (2011).","journal-title":"J. Crit. Care"},{"key":"64142_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jjcc.2020.02.012","volume":"76","author":"K Tsujita","year":"2020","unstructured":"Tsujita, K., Deguchi, H., Uda, A. & Sugano, K. Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: a nationwide database study. J. Cardiol. 76, 51\u201357 (2020).","journal-title":"J. Cardiol."},{"key":"64142_CR23","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/jgh.16989","volume":"40","author":"M Baik","year":"2025","unstructured":"Baik, M., Jeon, J., Yoo, J. & Kim, J. Effect of Potassium-Competitive Acid Blockers on Upper Gastrointestinal Bleeding in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study. J. Gastroenterol. Hepatol. 40, 1686\u20131694 (2025).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"64142_CR24","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1111\/bcp.15268","volume":"88","author":"E Yang","year":"2022","unstructured":"Yang, E. et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J. Clin. Pharmacol. 88, 3288\u20133296 (2022).","journal-title":"Br J. Clin. Pharmacol."},{"key":"64142_CR25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40262-023-01228-4","volume":"62","author":"E Yang","year":"2023","unstructured":"Yang, E., Ji, S. C., Jang, I-J. & Lee, S. Evaluation of CYP2C19-mediated pharmacokinetic drug interaction of tegoprazan, compared with vonoprazan or esomeprazole. Clin. Pharmacokinet. 62, 599\u2013608 (2023).","journal-title":"Clin. Pharmacokinet."},{"key":"64142_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/apt.16477","volume":"54","author":"SH Kim","year":"2021","unstructured":"Kim, S. H. et al. Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment. Pharmacol. Ther. 54, 402\u2013411 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"64142_CR27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","volume":"11","author":"GN Levine","year":"2014","unstructured":"Levine, G. N. et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat. Rev. Cardiol. 11, 597\u2013606 (2014).","journal-title":"Nat. Rev. Cardiol."},{"key":"64142_CR28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","volume":"374","author":"ML O\u2019Donoghue","year":"2009","unstructured":"O\u2019Donoghue, M. L. et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374, 989\u2013997 (2009).","journal-title":"Lancet"},{"key":"64142_CR29","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/j.1365-2036.2010.04247.x","volume":"31","author":"C Kwok","year":"2010","unstructured":"Kwok, C. & Loke, Y. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment. pharmacol. Ther. 31, 810\u2013823 (2010).","journal-title":"Aliment. pharmacol. Ther."},{"key":"64142_CR30","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1345\/aph.1M051","volume":"43","author":"NB Norgard","year":"2009","unstructured":"Norgard, N. B., Mathews, K. D. & Wall, G. C. Drug\u2013drug interaction between clopidogrel and the proton pump inhibitors. Ann. Pharmacother. 43, 1266\u20131274 (2009).","journal-title":"Ann. Pharmacother"},{"key":"64142_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/clpt.2010.219","volume":"89","author":"D Angiolillo","year":"2011","unstructured":"Angiolillo, D. et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin. Pharmacol. Ther. 89, 65\u201374 (2011).","journal-title":"Clin. Pharmacol. Ther."},{"key":"64142_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","volume":"51","author":"M Gilard","year":"2008","unstructured":"Gilard, M. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 51, 256\u2013260 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"64142_CR33","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3904\/kjim.2024.399","volume":"40","author":"OH Lee","year":"2025","unstructured":"Lee, O. H., Roh, J. W., Kim, Y., Im, E. & Cho, D. K. Effect of tegoprazan on temporal variability of platelet reactivity in patients treated with clopidogrel after coronary stenting. Korean J. Intern. Med. 40, 759\u2013766 (2025).","journal-title":"Korean J. Intern. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64142-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64142-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64142-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:25:09Z","timestamp":1789482309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64142-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["64142"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-64142-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Yongcheol Kim reports research grants from HK inno.N, Chong Kun Dang, and Jeilpharm. The remaining authors declare no conflicts of interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28748"}}